AMINOCAPROIC ACID

Fetal Risk Summary

Aminocaproic acid is used to enhance hemostasis when fibrinolysis contributes to bleeding. Animal reproduction studies have not been conducted with the drug (1).

No reports describing the placental passage of aminocaproic acid have been located. The molecular weight (approximately 131) is low enough, however, that passage to the fetus should be expected.

Aminocaproic acid was used during the 2nd trimester in a patient with subarachnoid hemorrhage as a result of multiple intracranial aneurysms (2). The drug was given for 3 days preceding surgery (dosage not given). No fetal toxicity was observed.

Breast Feeding Summary

No reports describing the use of aminocaproic acid during lactation have been located. Although the molecular weight (approximately 131) is low enough that excretion into breast milk should be expected, the indication for the drug probably implies that the chance of its use during nursing is very small.

References

1. Product information. Amicar. Immunex, 2000.
2. Willoughby JS. Sodium nitroprusside, pregnancy and multiple intracranial aneurysms. Anaesth Intensive Care 1984;12:358–60.